SEAGEN

seagen-logo

Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a... humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

#SimilarOrganizations #People #Financial #Event #Website #More

SEAGEN

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical Therapeutics

Founded:
1998-01-01

Address:
Bothell, Washington, United States

Country:
United States

Website Url:
http://www.seagen.com

Total Employee:
1001+

Status:
Active

Contact:
6192707227

Email Addresses:
[email protected]

Total Funding:
1.74 B USD

Technology used in webpage:
Content Delivery Network IPv6 Microsoft Azure DNS ReCAPTCHA V2 Microsoft ASP.NET Ajax Google Cloud Global Multi-Region Google Analytics IP Anonymization Google Cloud CDN Level 3 Communications


Similar Organizations

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.


Current Advisors List

david-w-gryska_image

David W. Gryska Board Member @ Seagen
Board_member
2005-01-01

david-w-gryska_image

David W. Gryska Board of Directors @ Seagen
Board_member

ted-w-love_image

Ted W. Love Board Member @ Seagen
Board_member
2020-08-01

srinivas-akkaraju_image

Srinivas Akkaraju Board Member @ Seagen
Board_member

daniel-g-welch_image

Daniel G. Welch Board of Directors @ Seagen
Board_member

Current Employees Featured

peter-senter_image

Peter Senter
Peter Senter VP, Chemistry @ Seagen
VP, Chemistry
2002-09-01

scott-orchard_image

Scott Orchard
Scott Orchard Senior Vice President and Associate General Counsel, Head of Transactional Law @ Seagen
Senior Vice President and Associate General Counsel, Head of Transactional Law

not_available_image

Swapnil Bhargava
Swapnil Bhargava Director, BioProcess Development @ Seagen
Director, BioProcess Development

peter-senter_image

Peter Senter
Peter Senter VP, Distinguished Research Fellow @ Seagen
VP, Distinguished Research Fellow
1998-08-01

wendel-doubleday_image

Wendel Doubleday
Wendel Doubleday Sr. Director, Chemical Development @ Seagen
Sr. Director, Chemical Development
2011-07-01

mark-cooley_image

Mark Cooley
Mark Cooley Executive Director, IT Strategy and Operations @ Seagen
Executive Director, IT Strategy and Operations
2020-03-01

monique-m-greer_image

Monique M. Greer
Monique M. Greer Vice President, Corporate Communications @ Seagen
Vice President, Corporate Communications
2018-03-01

roger-dansey_image

Roger Dansey
Roger Dansey Chief Medical Officer @ Seagen
Chief Medical Officer

michael-gerstle_image

Michael Gerstle
Michael Gerstle Director @ Seagen
Director
2019-12-01

scott-r-peterson_image

Scott R. Peterson
Scott R. Peterson Senior Vice President and Head of Research @ Seagen
Senior Vice President and Head of Research
2020-03-01

Founder


clay-siegall_image

Clay Siegall

Stock Details


Company's stock symbol is NASDAQ:SGEN

Acquisitions List

Date Company Article Price
2018-01-31 Cascadian Therapeutics Cascadian Therapeutics acquired by Seagen 614 M USD

Investors List

merck-co-inc_image

Merck

Merck investment in Post-IPO Equity - Seagen

takeda-pharmaceutical_image

Takeda

Takeda investment in Post-IPO Equity - Seagen

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Post-IPO Equity - Seagen

sofinnova-ventures_image

Sofinnova Investments

Sofinnova Investments investment in Venture Round - Seagen

Investments List

Date Company Article Money raised
2015-06-11 Cogent Biosciences Seagen investment in Series B - Cogent Biosciences 65 M USD

Official Site Inspections

http://www.seagen.com Semrush global rank: 746.98 K Semrush visits lastest month: 54.08 K

  • Host name: 13.107.253.41
  • IP address: 13.107.253.41
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Seagen" on Search Engine